ATI-2173
- Generic Name
- ATI-2173
A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects
Phase 1
Completed
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05137600
- Locations
- 🇨🇦
Altasciences, Montréal, Quebec, Canada
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
Phase 2
Terminated
- Conditions
- Hepatitis DHepatitis B, Chronic
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04847440
- Locations
- 🇲🇩
Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit, Chisinau, Republic Of Moldova, Moldova, Republic of
🇺🇦Medical Center of Limited Liability Company "Harmoniya krasy", Kyiv, Ukraine
A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 in Healthy Subjects and Subjects With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- Antios Therapeutics, Inc
- Target Recruit Count
- 88
- Registration Number
- NCT04248426
- Locations
- 🇺🇦
Medical Center of Limited Liability Company "Harmoniya krasy" Department of Clinical Trials, Kyiv, Ukraine
🇲🇩Republican Clinical Hospital "Timofei Mosneaga" Arensia EM Unit, Chisinau, Republic Of Moldova, Moldova, Republic of
🇨🇦Altasciences, Montréal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath